Our Mission
Monopar Therapeutics strives to develop proprietary therapeutics designed to extend life or improve the quality of life for cancer patients
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar is building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages, leveraging its scientific and clinical expertise to help reduce the risk and accelerate the clinical development of its drug product candidates.
Monopar's team is located in San Francisco, CA and Chicago, IL.
Licensing, developing and commercializing transformative oncology therapeutics
Multiple factors drive our passion for oncology
The numbers behind our research define Validive and camsirubicin opportunities
Monopar’s pipeline consists of Validive®(clonidine HCI MBT), a mucoadhesive buccal tablet for the prevention of chemoradiotherapy-induced severe oral mucositis (SOM) in oropharyngeal cancer (OPC) patients; camsirubicin, a proprietary analog of doxorubicin for the treatment of advanced soft tissue sarcoma, engineered specifically to minimize toxic effects on the heart while retaining anticancer activity; MNPR-101 RIT, a preclinical-stage radio-immuno-therapeutic (RIT) for the treatment of advanced solid cancers and severe COVID-19; MNPR-101, a preclinical-stage monoclonal antibody for the treatment of solid cancers; and MNPR-202, an early-stage preclinical camsirubicin analog which has potential in doxorubicin resistant cancers and as an immunogenic chemotherapy in combination with checkpoint inhibitors.
Product | Indications | Preclinical | Phase 1 | Phase 2 | Phase 3 | Status |
---|---|---|---|---|---|---|
Validive® |
Chemoradiation induced SOM |
Preclinical complete |
Phase 1 complete |
Phase 2 in progress |
Phase 3 not started |
Phase 2b/3 VOICE trial ongoing in US and EU |
Camsirubicin |
Advanced Soft Tissue Sarcoma |
Preclinical complete |
Phase 1 in progress |
Phase 2 not started |
Phase 3 not started |
Phase 1b trial ongoing in the US |
MNPR-101 RIT |
Advanced Solid Cancers, Severe COVID-19 |
Preclinical in progress |
Phase 1 not started |
Phase 2 not started |
Phase 3 not started |
Collaboration with NorthStar |
MNPR-101 |
Solid Cancers |
Preclinical in progress |
Phase 1 not started |
Phase 2 not started |
Phase 3 not started |
Late preclinical |
MNPR-202 |
Advanced Solid Cancers |
Preclinical in progress |
Phase 1 not started |
Phase 2 not started |
Phase 3 not started |
Early preclinical |